BioSpace News Archive

Protagonist Therapeutics, Inc. reported that on June 30, 2021, it issued an inducement award to Patrick Smith, the Company’s recently hired Vice President, Quality Assurance, in accordance with the terms of Mr. Smith’s employment offer letter.

Tomorrow is Canada Day and after months of collective efforts to reduce COVID-19 activity levels and increase first and second dose COVID-19 vaccine coverage, we can all have a sense of pride in having supported each other.

Hoag is now enrolling patients in a clinical trial to study an innovative surgical procedure that would allow surgeons to repair a patient’s mitral valve without open-heart surgery.

CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced results from the final analysis of its 40,000 subject international pivotal Phase 2b/3 study (the HERALD study) of the first-generation COVID-19 vaccine candidate, CVnCoV.

Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), today announces topline results for SARA-INT phase 2 study will be released in August 2021.

Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), today announces it has secured contracts with a major global Custom Development and Manufacturing Organization (CDMO) for the manufacturing of registration batches of Sarconeos (BIO101).

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced a partnership with Seegene, Inc., a global leader in multiplex molecular diagnostics, for the clinical development and commercialization of infectious disease molecular diagnostic products.

Helix BioPharma Corp. (TSX:HBP) (‘Helix’ or the ‘Company’), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Heman Chao has notified the Board of Directors of the Company of his intention to step down from the position of Chief Executive Officer (“CEO”), Chief Scientific Officer (“CSO”) and member of the Board, effective September 1, 2021

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the closing of its previously announced initial public offering of 14,000,000 shares of its common stock at a price to the public of $17.00 per share on June 29, 2021.

Amedisys, Inc., a leading home health, hospice and personal care company, announced that it has signed a definitive agreement to acquire Contessa Health, a leader in hospital-at-home and skilled nursing facility at-home services.